New scan could predict hormone therapy success in breast cancer

NCT ID NCT02409316

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a special PET/CT scan using a radioactive tracer called FES to see estrogen receptor activity in women with advanced, hormone-resistant breast cancer. The goal was to see if the scan could predict how well a new hormone therapy would work. Only 6 people were enrolled before the study was stopped early, so the findings are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
[18F]Fluoroestradiol (FES) - a radioactive tracer used in PET/CT scans
What this could lead to
If successful, this imaging method could help doctors predict how well hormone therapy will work in metastatic breast cancer, guiding more personalized treatment.
What could go wrong
This was a very small, early-phase study that was terminated early, so results are limited. The scan is not yet proven to improve outcomes and may not be widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Pennsylvania Hospital

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.